E
Cosmos Health Inc. COSM
$0.5125 $0.02996.20%
Recommendation
Sell
Prev Close
$0.5125
Volume
104
Avg Vol (90D)
404,092
Market Cap
$10.77M
Dividend & Yield
--
52-Week Range
$0.4403 - $1.58
P/E (TTM)
--
EPS (TTM)
-$2.23
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Cosmos Health Inc. (NASDAQ:COSM) Might Not Be As Mispriced As It Looks After Plunging 31%
3/4/2025 - Simply Wall St
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
2/26/2025 - Accesswire
Insider Buying: Cosmos Health Inc. (NASDAQ:COSM) CEO Purchases 354,296 Shares of Stock
2/26/2025 - MarketBeat
Video: Tuesday 2/25 Insider Buying Report: COSM, SEPN
2/25/2025 - Market News Video
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
2/18/2025 - Accesswire
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
2/11/2025 - Accesswire
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market
2/10/2025 - Accesswire
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
2/10/2025 - Accesswire
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
2/7/2025 - Accesswire
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
2/6/2025 - Accesswire
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market
2/5/2025 - Accesswire
Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas Purchases 51,414 Shares
2/1/2025 - MarketBeat
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow
1/28/2025 - Accesswire
Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion
1/27/2025 - Accesswire
Cosmos Health Inc. (NASDAQ:COSM) CEO Buys $29,953.00 in Stock
1/24/2025 - MarketBeat
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
1/23/2025 - Accesswire
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million
1/22/2025 - Accesswire
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
1/21/2025 - Accesswire
Market Might Still Lack Some Conviction On Cosmos Health Inc. (NASDAQ:COSM) Even After 31% Share Price Boost
1/18/2025 - Simply Wall St
Cosmos Health Inc. (NASDAQ:COSM) CEO Purchases $50,000.00 in Stock
1/17/2025 - MarketBeat
Cosmos Health Inc. (NASDAQ:COSM) CEO Buys $99,836.26 in Stock
1/15/2025 - MarketBeat
Video: Tuesday 1/14 Insider Buying Report: SNDA, COSM
1/14/2025 - Market News Video
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
1/13/2025 - Accesswire
Cosmos Health Inc. (NASDAQ:COSM) CFO Georgios Terzis Buys 85,778 Shares
12/27/2024 - MarketBeat
Cosmos Health Strengthens RandD Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
12/26/2024 - Accesswire
Income Statement
Total Revenue (TTM)
$56.04M
EBITDA (TTM)
-$19.04M
EBIT (TTM)
-$20.16M
Net Income (TTM)
-$20.39M
Balance Sheet
Total Assets (Q)
$64.52M
Total Debt (Q)
$11.02M
Total Liabilities (Q)
$29.54M
Book Value Per Share (Q)
$1.50
Cash Flow
Cash from Operations (TTM)
-$2.93M
Cash from Investing (TTM)
-$3.15M
Cash from Financing (TTM)
$7.72M
Net Change in Cash (TTM)
$954.20K
Filings
Filing Date
Thursday, November 14, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
1.85
7-Day Total Return
-4.21%
30-Day Total Return
-34.60%
60-Day Total Return
-32.05%
90-Day Total Return
-33.18%
Year to Date Total Return
-25.29%
1-Year Total Return
-33.09%
2-Year Total Return
-88.03%
3-Year Total Return
-99.33%
5-Year Total Return
-99.02%
52-week Low
Mar 04, 2025 - $0.4403
52-week High
Aug 21, 2024 - $1.58
Valuation
Market Cap
$10.77M - Nano Cap
Enterprise Value
$18.46M
Price/Sales (TTM)
0.17
Price/Book (Q)
0.34
Dividends and Shares
Shares Outstanding
18.42M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cosmosholdingsinc.com
Phone Number
312 536 3102
Address
141 West Jackson Boulevard
Chicago, IL 60604
Country
United States
Year Founded
2009
Business Description
Sector
Health Care
Industry
Health Care Equipment and Services
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC... more
NASDAQ 03/07/2025 3:00PM Eastern Quotes delayed
Weiss Ratings